Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
Decaudin
Didier
D
Etienne
Marie-Christine
MC
De Cremoux
Patricia
P
Maciorowski
Zofia
Z
Vantelon
Jean-Marie
JM
Voog
Eric
E
Urien
SaIk
S
Tran-Perennou
Carine
C
Renée
Nicole
N
Vielh
Philippe
P
Némati
Fariba
F
Pouillart
Pierre
P
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004334:Drug Administration Schedule; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D005240:Feasibility Studies; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen